These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 28219022)

  • 1. Rationale for stimulator of interferon genes-targeted cancer immunotherapy.
    Rivera Vargas T; Benoit-Lizon I; Apetoh L
    Eur J Cancer; 2017 Apr; 75():86-97. PubMed ID: 28219022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. STING, DCs and the link between innate and adaptive tumor immunity.
    Vatner RE; Janssen EM
    Mol Immunol; 2019 Jun; 110():13-23. PubMed ID: 29273394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Cytosolic Nucleic Acid-Sensing Pathways for Cancer Immunotherapies.
    Iurescia S; Fioretti D; Rinaldi M
    Front Immunol; 2018; 9():711. PubMed ID: 29686682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. STING Signaling in Cancer Cells: Important or Not?
    Sokolowska O; Nowis D
    Arch Immunol Ther Exp (Warsz); 2018 Apr; 66(2):125-132. PubMed ID: 28748479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer.
    Corrales L; Gajewski TF
    Clin Cancer Res; 2015 Nov; 21(21):4774-9. PubMed ID: 26373573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nucleic Acid Sensing Machinery: Targeting Innate Immune System for Cancer Therapy.
    Iurescia S; Fioretti D; Rinaldi M
    Recent Pat Anticancer Drug Discov; 2018; 13(1):2-17. PubMed ID: 29086701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting STING for cancer immunotherapy: From mechanisms to translation.
    Huang R; Ning Q; Zhao J; Zhao X; Zeng L; Yi Y; Tang S
    Int Immunopharmacol; 2022 Dec; 113(Pt A):109304. PubMed ID: 36252492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune Pathways.
    Li K; Qu S; Chen X; Wu Q; Shi M
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28216575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Function of cGAS-STING Pathway in Treatment of Pancreatic Cancer.
    Mohseni G; Li J; Ariston Gabriel AN; Du L; Wang YS; Wang C
    Front Immunol; 2021; 12():781032. PubMed ID: 34858438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive elaboration of the cGAS-STING signaling axis in cancer development and immunotherapy.
    Zheng J; Mo J; Zhu T; Zhuo W; Yi Y; Hu S; Yin J; Zhang W; Zhou H; Liu Z
    Mol Cancer; 2020 Aug; 19(1):133. PubMed ID: 32854711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insight into the dichotomous regulation of STING activation in immunotherapy.
    Hu Z; Yang Y; Fang L; Zhou J; Zhang H
    Immunopharmacol Immunotoxicol; 2021 Apr; 43(2):126-137. PubMed ID: 33618600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Danger signals: Chemotherapy enhancers?
    Rivera Vargas T; Apetoh L
    Immunol Rev; 2017 Nov; 280(1):175-193. PubMed ID: 29027217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical applications of STING agonists in cancer immunotherapy: current progress and future prospects.
    Wang B; Yu W; Jiang H; Meng X; Tang D; Liu D
    Front Immunol; 2024; 15():1485546. PubMed ID: 39421752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors.
    Woo SR; Fuertes MB; Corrales L; Spranger S; Furdyna MJ; Leung MY; Duggan R; Wang Y; Barber GN; Fitzgerald KA; Alegre ML; Gajewski TF
    Immunity; 2014 Nov; 41(5):830-42. PubMed ID: 25517615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An updated patent review of stimulator of interferon genes agonists (2021 - present).
    Xin GF; Chen NN; Li LL; Liu XC; Che CC; Wu BD; You QD; Xu XL
    Expert Opin Ther Pat; 2024 May; 34(5):297-313. PubMed ID: 38849323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. cGAS-STING and Cancer: Dichotomous Roles in Tumor Immunity and Development.
    Ng KW; Marshall EA; Bell JC; Lam WL
    Trends Immunol; 2018 Jan; 39(1):44-54. PubMed ID: 28830732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. STING, nanoparticles, autoimmune disease and cancer: a novel paradigm for immunotherapy?
    Lemos H; Huang L; McGaha T; Mellor AL
    Expert Rev Clin Immunol; 2015 Jan; 11(1):155-65. PubMed ID: 25521938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. STING-mediated DNA sensing in cancer immunotherapy.
    Zhou X; Jiang Z
    Sci China Life Sci; 2017 Jun; 60(6):563-574. PubMed ID: 28639100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KDM5 histone demethylases repress immune response via suppression of STING.
    Wu L; Cao J; Cai WL; Lang SM; Horton JR; Jansen DJ; Liu ZZ; Chen JF; Zhang M; Mott BT; Pohida K; Rai G; Kales SC; Henderson MJ; Hu X; Jadhav A; Maloney DJ; Simeonov A; Zhu S; Iwasaki A; Hall MD; Cheng X; Shadel GS; Yan Q
    PLoS Biol; 2018 Aug; 16(8):e2006134. PubMed ID: 30080846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type I interferons and dendritic cells in cancer immunotherapy.
    Sprooten J; Agostinis P; Garg AD
    Int Rev Cell Mol Biol; 2019; 348():217-262. PubMed ID: 31810554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.